BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. Our mission is to enable scientists to eliminate disease and suffering through novel application of computational technologies and translating these findings directly and rapidly to clinical use.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

BIOCONSORTIA SHOWCASES BREAKTHROUGH MICROBIAL PRODUCTS AND PIPELINE OF INNOVATION

BioConsortia, Inc. | September 05, 2022

news image

BioConsortia’s innovative microbial products and technical capabilities were on full display August 30th at its Davis, CA headquarters in an investor-focused Technology Showcase event. BioConsortia demonstrated rapid advancements in microbial product and pipeline developments for reducing nitrogen fertilizers, controlling soil pests and plant diseases for larger and better-quality crop yields, as well as protecting crops post-harvest to avoid food waste, while minimizing environmental impa...

Read More

Medical, Industry Outlook

ERS GENOMICS & SANTA CRUZ BIOTECHNOLOGY ENTER INTO CRISPR/CAS9 LICENSING AGREEMENT

PRNewswire | August 14, 2023

news image

ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Santa Cruz Biotechnology Inc ('SCBT,'). This is a non-exclusive licensing agreement granting SCBT access to the ERS CRISPR/Cas9 patent portfolio. ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. Consequently, the ERS patent portfolio is the most comprehensive collection of proprietary rights to this gene editing technology. ...

Read More

Diagnostics

CANCER CELL PAPER IDENTIFIES "AVIDITY ENHANCEMENT" AS NEW STRATEGY FOR IMPROVING CAR T THERAPY FOR ACUTE MYELOID LEUKEMIA

LUMICKS | May 26, 2022

news image

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML). AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...

Read More

Industrial Impact

EYEBIO RAISES $65M IN SERIES A FUNDING TO DEVELOP NEW GENERATION OF EYE DISEASE THERAPIES

Eyebiotech Limited | February 23, 2022

news image

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking o...

Read More
news image

Industrial Impact

BIOCONSORTIA SHOWCASES BREAKTHROUGH MICROBIAL PRODUCTS AND PIPELINE OF INNOVATION

BioConsortia, Inc. | September 05, 2022

BioConsortia’s innovative microbial products and technical capabilities were on full display August 30th at its Davis, CA headquarters in an investor-focused Technology Showcase event. BioConsortia demonstrated rapid advancements in microbial product and pipeline developments for reducing nitrogen fertilizers, controlling soil pests and plant diseases for larger and better-quality crop yields, as well as protecting crops post-harvest to avoid food waste, while minimizing environmental impa...

Read More
news image

Medical, Industry Outlook

ERS GENOMICS & SANTA CRUZ BIOTECHNOLOGY ENTER INTO CRISPR/CAS9 LICENSING AGREEMENT

PRNewswire | August 14, 2023

ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Santa Cruz Biotechnology Inc ('SCBT,'). This is a non-exclusive licensing agreement granting SCBT access to the ERS CRISPR/Cas9 patent portfolio. ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. Consequently, the ERS patent portfolio is the most comprehensive collection of proprietary rights to this gene editing technology. ...

Read More
news image

Diagnostics

CANCER CELL PAPER IDENTIFIES "AVIDITY ENHANCEMENT" AS NEW STRATEGY FOR IMPROVING CAR T THERAPY FOR ACUTE MYELOID LEUKEMIA

LUMICKS | May 26, 2022

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML). AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...

Read More
news image

Industrial Impact

EYEBIO RAISES $65M IN SERIES A FUNDING TO DEVELOP NEW GENERATION OF EYE DISEASE THERAPIES

Eyebiotech Limited | February 23, 2022

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking o...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us